FDC working capital

Per cent unless marked ×
Tap a line for its trendLast 12Mto Sep 2026FY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
187.46×187.46×189.35×199.54×176.22×
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
21.90×21.90×19.58×22.55×20.96×
105.74×105.74×96.96×101.39×87.78×
103.62×103.62×111.97×120.70×109.40×
3.00×2.83×2.91×2.42×2.36×
0.77×0.77×0.81×0.81×0.77×
0.71×0.71×1.19×0.72×0.80×
0.58×0.58×0.98×0.65×0.62×
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

FDC₹377.15

FDC Limited

· Pharma & Health
₹ CrorePeersIOLCPMOREPENLABINNOVACAPORCHPHARMASENORESGUJTHEMRPGLIFESANOFIMcap ₹6,140 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/09/2026
Inventory Days (DIO)176.22199.54189.35187.46187.46
Receivable Days (DSO)20.9622.5519.5821.9021.90
Payable Days (DPO)87.78101.3996.96105.74105.74
Cash Conversion Cycle (days)109.40120.70111.97103.62103.62
Working Capital Turnover2.362.422.912.833.00
Asset Turnover0.770.810.810.770.77
Cash Conversion (CFO/Net Income)0.800.721.190.710.71
CFO/EBITDA0.620.650.980.580.58
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.